Miyagi Cancer Center

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials

Phase

• Phase 32 trials

Status

• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company2 trials

Running trials

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Tatsuro Fukuhara (principal investigator)

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

  Contact: Tatsuro Fukuhara (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting